Avid Bioservices Inc (CDMO)

[biopharm]

Stafford lies to Peregrine Pharmaceuticals and the only thing Ronin Capital Management is concerned with is buying up Xencor shares and David Szymkowski in on the puppet show it seems with Roche in tow

Reduction in MDSCs was always part of the MOA of PS Targeting so how many will attempt to profit due to PS Targeting patents?

Why are many MOA of drugs not saying they target flipped PS? Is it because those patents/rights belong to Peregrine Pharmaceuticals where John Springs Stafford came in with one clear mission, to work with hedge fund and move the IP to Oncologie where the current BOD at Avid Bioservices would not stand up for their fiduciary duties?

John Springs Stafford, profiting off all this illegally?




___

From Little Known to IPO: INmune Bio Raises $8.16 Million in Trading Debut

By Jared Whitlock

Monday, February 4, 2019

In the first biotech initial public offering of the year, La Jolla-based INmune Bio took in $8.16 million during its trading debut. The Nasdaq listing also raised the profile of what’s been a quiet operation.

INmune Bio skipped the large funding rounds – and media fanfare – that typically precede an IPO. That was so management could keep control of the company, and because INmune Bio expects its clinical trials will be relatively inexpensive, a company executive said.

The company wants to reengineer the immune system to stop cancer recurrence. During its inaugural day of trading on Feb. 1, INmune Bio sold 1,020,560 shares of common stock at $8 per share.

"Most of the community has not heard of us, and we've done that somewhat on purpose,” Chief Financial Officer David Moss told the San Diego Business Journal.

The company’s INKmune is designed to make NK cells that would otherwise ignore cancer attack the disease. It will start clinical trials in women with refractory ovarian cancer around the end of March, Moss said.

"We focus on properly signaling the NK cells so that they can resume immune surveillance and help clean up residual disease, with the hope that people may not relapse as much,” Moss said.

INmune’s second program, INB03, seeks to inhibit myeloid derived suppressor cells, which often cause treatment resistance. INB03 started a phase 1 trial in Australia in the third quarter of 2018.

INKmune and INB03 could potentially be used alone, together, or in combination with other therapies. They’re aimed at a wide range of cancers.

By holding clinical trials in the United Kingdom and Australia, the company intends to keep costs down. The countries offer tax rebates.

The $8.16 million raised, according to Moss, should advance the programs to Phase 2 trials. From there, he envisions the company turning to grants, partnerships or the public markets -- or all of the above.

"Our belief is that the biotech industry is driven by data. If we drive data for our programs, that will certainly drive value, and that will certainly drive the ability to finance them further,” Moss said.

Although the government shutdown halted IPOs, INmune Bio wasn’t affected. The company got approval to list shares right before the shutdown furloughed U.S. Securities and Exchange Commission employees who review IPO paperwork, but held off on account of the holidays and attention being on the annual J.P. Morgan Healthcare Conference in January.

INmune Bio, which contracts out clinical trial work, has three employees. The company plans to add workers.

Elsewhere in San Diego biotech, Gossamer Bio plans to go public Feb. 8. During the shutdown Gossamer sought to sidestep SEC review, but later reverted to a traditional IPO path with the government reopening.

In addition, Cirius Therapeutics, Cibus and Poseida Therapeutics have put in IPO paperwork, but have yet to list shares.

https://www.sdbj.com/news/2019/feb/04/inmune-bio-raises-816-million-through-ipo/

_____



Corporate Overview

Taking the brakes off of the most powerful weapon in the fight against disease: our immune system

INmune Bio Inc. is a clinical stage biotechnology company that is developing new immunotherapies that reprogram a patient’s innate immune system to allow the immune system to fight cancer and Alzheimer’s.

INmune Bio Inc. is a developing novel therapies targeting distinct parts of a patient’s innate immune system to fight disease. Drug candidates, INKmune™ and INB03, may be used to treat cancer. XPro1595 targets neuroinflammation as a cause of Alzheimer’s disease. INmune Bio’s product platforms utilize a precision therapy approach, promoting the body’s innate immune response to treat unsolved problems in medicine.

David Szymkowski, PhD
David E. Szymkowski leads the immunology group as Vice President of Cell Biology at Xencor Inc where he is focused on translational development of Fc-engineered and bispecific antibodies for the treatment of autoimmune diseases, allergic diseases, and cancer. Prior to joining Xencor in 2002, Dr. Szymkowski was a principal scientist in the respiratory group at Roche Bioscience in Palo Alto, CA. Previously, he was a virology program leader at Roche Pharmaceuticals in the U.K. With 25 years of big pharma and biotech R&D experience at Roche and at Xencor, Dr. Szymkowski has been instrumental in 10 IND submissions, coauthored over forty papers and reviews, is an inventor on over a dozen patents, and speaks frequently on the development of antibody therapeutics and other biologics. Dr. Szymkowski has contributed to the advancement of numerous antibody drugs into clinical trials for lupus, asthma, allergy, and hematological and solid tumors. He received his B.A. at Johns Hopkins University and his Ph.D. in molecular and cell biology from Penn State, and completed a postdoc at the Imperial Cancer Research Fund (U.K.).

https://quotes.wsj.com/XNCR/company-people

Most Recent Insider Transactions
June 2018 - May 2019
Filing Date Name/Title Shares Transaction Value
05/02/19
Ronin Capital LLC
14,611 Acquisition at $29.87 per share 436,431
03/25/19
Ronin Capital LLC
3,500 Acquisition at $29.77 per share 104,195
03/22/19
Ronin Capital LLC
2,000 Acquisition at $29.96 per share 59,920
03/18/19
Ronin Capital LLC
1,100 Acquisition at $29.90 per share 32,890
03/15/19
Ronin Capital LLC
38,300 Acquisition at $29.02 per share 1,111,466